Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Non-Alcoholic Fatty Liver Disease (PARADISE-NAFLD)

Inclusion Criteria: * 18 years or older at the time of screening. * Total liver fat content ≥10% measured by MRI-PDFF. * Body mass index (BMI) ≥ 25 kg/m\^2. * The anteroposterior, transverse and axial diameters of inferior perirenal fat pad measured by ultrasound should be at least 20mm. * Participants should be willing to sign the informed consent form of the study. Exclusion Criteria: * History of significant alcohol consumption (significant alcohol consumption was defined as more than 140 g/week in females and more than 210 g/week in males in the last 12months before screening, on average). * Secondary factors causing hepatic steatosis, including viral hepatitis C, autoimmune hepatitis, total parenteral nutrition, celiac disease, Wilson's disease, hypothyroidism, hereditary hemochromatosis, drug factors (amiodarone, glucocorticoids, methotrexate, tamoxifen), etc. * Complicating other chronic liver diseases, mainly including viral hepatitis, cholestatic liver disease, drug-induced liver injury, etc. * Weight change \>10% in the past 3 months. * Clinical or pathological diagnosis of cirrhosis. * NAFLD treatment drugs (such as vitamin E, obecholic acid, thiazolidinediones, etc.) were used within 6 months before enrollment. * History of bariatric surgery. * History of kidney and/or surrounding tissue surgery. * Waist skin infection. * Urinary stones and/or hematuria (positive for gross hematuria or occult blood). * Unstable cardiovascular diseases: (1) Myocardial infarction, unstable angina pectoris or cerebrovascular accident occurred in the last 6 months. (2) Persistent atrial fibrillation without anticoagulation. (3) Severe structural heart disease (including valvular heart disease, cardiomyopathy). (4) second degree and above atrioventricular block and/or sick sinus syndrome. (5) Uncontrolled hypertension. * Type 1 diabetes or uncontrolled hyperglycemia (HBA1c ≥ 9.5%). * Participants with untreated tumors. * Laboratory screening results include one or more of the following: (1) Neutrophil absolute value \<1.0x10\^9/L. (2) Platelet count \<100x10\^9/L. (3) Hemoglobin \<100g/L. (4) Albumin \<35g/L. (5) International standard value \>1.5. (6) Total bilirubin \>1.5 times the upper limit of normal value. (7) The estimated glomerular filtration rate was \<60ml/ (minx1.73m\^2). * Participants who are pregnant, breastfeeding or trying to conceive. * Any contraindication or inability to obtain an MRI. * Participants who were unable to follow up. * Any other situation that the investigator considers to be detrimental to the patient's health, hindering the completion of the study, or interfering with the results of the study.